A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients

To evaluate the preliminary efficacy and safety of HH-120 nasal spray in the treatment of asymptomatic or mild COVID-19.

Inclusion Criteria:18 to 65 years old.Participants with mild COVID-19 with symptom onset≤5 days or asymptomatic COVID-19.Participants being able and willing to provide informed consent prior to any study-specific procedure.Exclusion Criteria:Participants with moderate or severe COVID-19.Participants within the pregnancy or breastfeeding period or plan to be pregnant during the study period.Participants requiring oxygen treatment (such as non-invasive ventilation, invasive mechanical ventilation, ECMO, etc.).Participants with nasal disease that is inconvenient or intolerant of nasal spray administration, or cannot use the nasal spray treatment.Participants with comorbid Malignancy or with a history of malignancy.Participants with active or uncontrolled systemic autoimmune disease.Insufficient function of key organs.Other reasons considered by the investigator to be unsuitable for the trial.